Navigation Links
New chemical probe provides tool to investigate role of malignant brain tumor domains
Date:3/1/2013

CHAPEL HILL, N.C. In an article published as the cover story of the March 2013 issue of Nature Chemical Biology, Lindsey James, PhD, research assistant professor in the lab of Stephen Frye, Fred Eshelman Distinguished Professor in the UNC School of Pharmacy and member of the UNC Lineberger Comprehensive Cancer Center, announced the discovery of a chemical probe that can be used to investigate the L3MBTL3 methyl-lysine reader domain. The probe, named UNC1215, will provide researchers with a powerful tool to investigate the function of malignant brain tumor (MBT) domain proteins in biology and disease.

"Before this there were no known chemical probes for the more than 200 domains in the human genome that recognize methyl lysine. In that regard, it is a first in class compound. The goal is to use the chemical probe to understand the biology of the proteins that it targets," said Dr. James.

Chromatin regulatory pathways play a fundamental role in gene expression and disease development, especially in the case of cancer. While many chemical probes work through the inhibition of enzyme activity, L3MBTL3 functions as a mediator of protein-to-protein interactions, which have been historically difficult to target with small, drug-like molecules.The researchers found three to four further disease subtypes within TN tumors, with more than 75 percent of the tumors falling into the basal-like subtype. Further research is needed to identify the distinct biomarkers shared by the expanded subtypes of TN cancers. The ultimate goal will be to target the individual biomarkers of these subtypes and create therapies that target their individual biology, according to Dr. Perou.

"Many people believe that protein-protein interactions are difficult to target. Often they have a large surface area, so it is hard for small molecules to go in and intervene," said Dr. James.

Almost 40 percent of the genes that drive cancer can be mapped to d
'/>"/>

Contact: William Davis
william_davis@med.unc.edu
919-962-3405
University of North Carolina Health Care
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Foods Might Serve Up High Levels of Chemicals Found in Plastics
2. American Chemical Society podcast: New super-nutritious puffed rice for breakfast cereals, snacks
3. Plastics Chemical BPA Common in Preemie ICU: Study
4. Flame Retardant Chemicals Market growing at a CAGR of 6.9% & to reach $7,131.9 Million by 2017 - New Report by MarketsandMarkets
5. Chemicals in Cookware, Carpets May Raise Arthritis Risk in Women
6. Chemicals From Antibacterial Products Found in Minnesota Lakes
7. Test for hormone-disrupting chemicals gets global seal of approval
8. Could Chemical in Dishware Raise Your Risk for Kidney Stones?
9. 2013 economic outlook for global chemical industry
10. New American Chemical Society podcast: Leaves of carob tree fight food-poisoning bacteria
11. New treatment could combat deadly chemical agents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New chemical probe provides tool to investigate role of malignant brain tumor domains
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
(Date:2/28/2015)... February 28, 2015 With their commitment ... has added an additional exercise to their already robust ... exercise is most commonly known as, is often performed ... Pulls” are executed in a relatively safe manner and ... strength levels. The full description of “Rope Pulls” is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With ... expert offers breast cancer survivors some guidance on what ... Karen Syrjala, director of biobehavioral sciences and co-director ... Research Center in Seattle, touches upon both the lingering ...
... The brain,s inner network becomes increasingly more efficient as ... measures, a joint study from the Ecole Polytechnique Fdrale ... in collaboration with Harvard Medical School, has verified these ... the PNAS early online edition last week, the soon-to-be-released ...
... genes respond to hormonal changes and inflammation has been ... a five-year study. The research programme at the ... (BRC) is led by Professor Julian Davis, a consultant ... University of Manchester,s Developmental Biomedicine Research Group. He ...
... , TUESDAY, Oct. 26 (HealthDay News) --Middle-aged adults ... as a result of radiation exposure as younger adults ... thought to be more sensitive to the long-term impact ... runs counter to some previous research suggesting that as ...
... Institute in Melbourne, Australia, has been awarded a Victorian Cancer ... and highly lethal form of ovarian cancer. Epithelial ovarian ... the ovary, accounts for 90 per cent of ovarian tumours. ... research has revealed that it may start in cells outside ...
... though the cancer-treatment agent cetuximab is not considered effective ... research indicates that patients with colorectal cancer not responding ... who were treated with cetuximab had longer overall and ... a study in the October 27 issue of ...
Cached Medicine News:Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:The brain's journey from early Internet to modern-day fiber optics -- all in 1 lifetime 2Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Cancer Risk From Radiation Doesn't Fade With Age 2Health News:VCA fellowship funding to extend ovarian cancer research 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 2012  Boehringer Ingelheim will present results from LUX-Lung ... investigating afatinib in patients with stage IIIB or ... epidermal growth factor receptor (EGFR) mutation (EGFR M+), ... Society of Clinical Oncology (ASCO) in Chicago, June ...
... May 16, 2012  Leading events organiser UBM Conferences ... announced details of the forthcoming CPhI Extractables and Leachables ... 2pm IST/9:30am GMT/4:30pm CST. The free to attend webinar ... extractables and leachables and during drug development, in addition ...
Cached Medicine Technology:Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 2Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 3Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 4Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 5Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 6Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 7Global Webinar Focuses on Considerations for Extractables and Leachables 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: